Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldesleukin + Anti-hCD70 CAR T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2|Interleukin-2|IL2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Anti-hCD70 CAR T cells||Anti-hCD70 CAR T cells consist of patient-derived peripheral blood lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) that targets CD70 and contains the extracellular region of CD27 fused to 41BB and CD3-zeta, which potentially inhibit the growth of CD70-expressing tumors (PMID: 27803044).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02830724||Phase Ib/II||Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR T cells||Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers||Recruiting||USA||0|